Department of Neurology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC.
Eur Neurol. 2011;66(2):110-6. doi: 10.1159/000328429. Epub 2011 Aug 18.
BACKGROUND/AIMS: Intravenous tissue plasminogen activator (tPA) treatment is recommended in acute stroke within 3 h of onset; however, the benefit of its use in the elderly remains uncertain. We assessed the safety and efficacy of tPA treatment in elderly patients.
We recruited 97 elderly Chinese patients aged ≥80 years with cerebral ischemia presenting within 3 h of onset. Favorable outcomes were defined as discharge to home and modified Rankin Scale (mRS) ≤2 at discharge.
For moderate to severe patients (NIHSS ≥6), the baseline characteristics between the tPA (n = 30) and non-tPA (n = 41) group were not different. The proportion of patients discharged home was 56.7 and 61%, respectively (p = 0.72). For patients with baseline mRS ≤2, the frequency of discharged mRS ≤2 was not different (27.3% of the tPA group and 26.9% of the non-tPA group; p = 1.00). Symptomatic intracranial hemorrhage was 6.7 and 2.4%, respectively (p = 0.31). For minor stroke patients (NIHSS ≤5), tPA was not considered and the outcome of those discharged home and mRS ≤2 was 73 and 88%, respectively.
Elderly patients can be treated safely with intravenous tPA, whereas our data did not support routine thrombolysis. Further randomized trials in the elderly are encouraged.
背景/目的:静脉注射组织型纤溶酶原激活剂(tPA)治疗推荐用于发病 3 小时内的急性脑卒中;然而,其在老年人中的获益仍不确定。我们评估了 tPA 治疗老年患者的安全性和有效性。
我们招募了 97 名年龄≥80 岁的中国老年脑缺血患者,发病 3 小时内。出院时的良好结局定义为出院回家和改良 Rankin 量表(mRS)≤2。
对于中重度患者(NIHSS≥6),tPA 组(n=30)和非 tPA 组(n=41)的基线特征无差异。出院回家的患者比例分别为 56.7%和 61%(p=0.72)。对于基线 mRS≤2 的患者,出院 mRS≤2 的频率无差异(tPA 组为 27.3%,非 tPA 组为 26.9%;p=1.00)。症状性颅内出血分别为 6.7%和 2.4%(p=0.31)。对于轻度脑卒中患者(NIHSS≤5),不考虑使用 tPA,出院回家和 mRS≤2 的患者比例分别为 73%和 88%。
老年患者可以安全地接受静脉注射 tPA 治疗,而我们的数据不支持常规溶栓。鼓励在老年人中进行进一步的随机试验。